Pirfenidone Combined With Methylprednisolone Versus Methylprednisolone in the Treatment of CIP
Status:
Recruiting
Trial end date:
2024-10-20
Target enrollment:
Participant gender:
Summary
Checkpoint inhibitor-related pneumonitis (CIP）is a common fatal immune-related adverse event
of PD-1/PD-L1 inhibitors. Some CIP patients have poor effect on hormone therapy, and the
remission time of CIP varies greatly. Antifibrotic drugs may be effective in patients with
CIP.